

RESEARCH ARTICLE

# Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Sulav Duwal<sup>1\*</sup>, Laura Dickinson<sup>2</sup>, Saye Khoo<sup>2</sup>, Max von Kleist<sup>1\*</sup>

**1** Department of Mathematics & Computer Science, Freie Universität Berlin, Germany, **2** Institute of Translational Medicine, University of Liverpool, United Kingdom

\* [sulav@zedat.fu-berlin.de](mailto:sulav@zedat.fu-berlin.de) (SD); [max.kleist@fu-berlin.de](mailto:max.kleist@fu-berlin.de) (MvK)



## Abstract

Currently, there is no effective vaccine to halt HIV transmission. However, pre-exposure prophylaxis (PrEP) with the drug combination Truvada can substantially decrease HIV transmission in individuals at risk. Despite its benefits, Truvada-based PrEP is expensive and needs to be taken once-daily, which often leads to inadequate adherence and incomplete protection. These deficits may be overcome by next-generation PrEP regimen, including currently investigated long-acting formulations, or patent-expired drugs. However, poor translatability of animal- and *ex vivo/in vitro* experiments, and the necessity to conduct long-term (several years) human trials involving considerable sample sizes (N>1000 individuals) are major obstacles to rationalize drug-candidate selection. We developed a prophylaxis modelling tool that mechanistically considers the mode-of-action of all available drugs. We used the tool to screen antivirals for their prophylactic utility and identify lower bound effective concentrations that can guide dose selection in PrEP trials. While *in vitro* measurable drug potency usually guides PrEP trial design, we found that it may over-predict PrEP potency for all drug classes except reverse transcriptase inhibitors. While most drugs displayed graded concentration-prophylaxis profiles, protease inhibitors tended to switch between none- and complete protection. While several treatment-approved drugs could be ruled out as PrEP candidates based on lack-of-prophylactic efficacy, darunavir, efavirenz, nevirapine, etravirine and rilpivirine could more potently prevent infection than existing PrEP regimen (Truvada). Notably, some drugs from this candidate set are patent-expired and currently neglected for PrEP repurposing. A next step is to further trim this candidate set by ruling out compounds with ominous safety profiles, to assess different administration schemes *in silico* and to test the remaining candidates in human trials.

## OPEN ACCESS

**Citation:** Duwal S, Dickinson L, Khoo S, von Kleist M (2019) Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. PLoS Comput Biol 15(1): e1006740. <https://doi.org/10.1371/journal.pcbi.1006740>

**Editor:** Sebastian Bonhoeffer, ETH Zürich, SWITZERLAND

**Received:** December 22, 2017

**Accepted:** December 20, 2018

**Published:** January 30, 2019

**Copyright:** © 2019 Duwal et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** MvK. and SD acknowledge financial support from the BMBF e:Bio junior research group 'Systems Pharmacology & Disease Control', grant number 031A307. SK has received funding from Gilead, Viiv Healthcare, Merck and Janssen for the HIV Drug Interactions website, and for research grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Author summary

Pre-exposure prophylaxis (PrEP) is a novel, promising strategy to halt HIV transmission. PrEP with Truvada can substantially decrease the risk of infection. However, individuals often inadequately adhere to the once-daily regimen and the drug is expensive. These

**Competing interests:** The authors have declared that no competing interests exist.

shortcomings may be overcome by next-generation PrEP compounds, including long-acting formulations. However, poor translatability of animal- and *ex vivo/in vitro* experiments, and difficulties in conducting long-term trials involving considerable sample sizes ( $N > 1000$  individuals) make drug-candidate selection and optimization of administration schemes costly and often infeasible. We developed a simulation tool that mechanistically considers the mode-of-action of all antivirals. We used the tool to screen all available antivirals for their prophylactic utility and identified lower bound effective concentrations for designing PrEP dosing regimen in clinical trials. We found that *in vitro* measured drug potency may over-predict PrEP potency, for all antiviral classes except reverse transcriptase inhibitors. We could rule out a number of antivirals for PrEP repurposing and predicted that darunavir, efavirenz, nevirapine, etravirine and rilpivirine provide complete protection at clinically relevant concentrations. Further trimming of this candidate set by compound-safety and by assessing different implementation schemes is envisaged.

## Introduction

Pre-exposure prophylaxis (PrEP) to prevent HIV infection (using drugs which are licensed for its treatment) has been assessed in people at high risk of sexual transmission. Of the available agents, once-daily tenofovir and emtricitabine (Truvada) have been extensively studied, and demonstrate protective efficacy (59–100% [1, 2]) in individuals who are adherent to the medication; conversely poor medication adherence explains the lack of protection observed in some trials [3]. However, major shortcomings of Truvada-based PrEP are its costs [4], a residual infection risk and the necessity for daily drug intake (which often leads to inadequate adherence). These deficits may be overcome by next-generation PrEP regimen, including patent-expired antivirals and long-acting formulations.

Studies assessing next-generation PrEP regimen are underway [5], but rational selection of which agents to advance into PrEP trials based on their intrinsic pharmacology and mode of action has not been comprehensively or systematically undertaken. Moreover, studies have focussed on patent-protected compounds [6], which are likely unaffordable in resource-constrained settings [4] hit hardest by the epidemic.

The considerable sample sizes ( $N > 1000$  individuals) and clinical trial duration required (years) to test any new candidate against tenofovir-emtricitabine, and the need to assess regimens with forgiveness for missed dosing or episodic, event-driven PrEP make the current strategy of empirical drug selection costly and prone to failure. We chose to explore an alternative strategy by developing a mathematical modelling tool to assess the per-contact efficacy of anti-HIV drugs. This approach allows prediction of prophylactic utility by integrating drug specific factors (pharmacokinetic/pharmacodynamic (PK/PD) attributes) and attributes of the targeted risk group in order to probe and discard candidates, accelerate drug development and markedly reduce costs. In this work, we are particularly interested in agents where existing patents had already, or are about to expire, in order to maximise the potential impact for low and middle income countries.

Various epidemiological modelling approaches have been used to predict the public health benefits of PrEP [7] and the risk of emergent drug resistance [8–10]. These approaches are highly dependent on *ad hoc* parameter assumptions [11] (specifically the per-contact PrEP efficacy), which may explain the different and contradictory predictions which have emerged.

Knowledge of the per-contact PrEP efficacy, ideally concentration-prophylaxis relationships, are currently lacking and parameters derived from animal models poorly translate into

human efficacy. Concentration-prophylaxis relationships are particularly critical to define lower concentrations in human trials that can attain e.g. > 90% protection: I.e., ideally a PrEP candidate should be dosed such that the concentrations stay above this target (e.g. 90% protection) and at the same time avoid adverse effects in all individuals. For prophylaxis, there is a general void of information regarding drug-specific and drug-class specific concentration-prophylaxis relationships. While the potency of drugs to inhibit HIV replication can readily be measured *in vitro*, researchers are often unaware that this measure of drug potency may not coincide with the potency to prevent HIV infection (prophylactic potency) and consequently PrEP trial design may be flawed, incurring costs and putting individuals at risk.

In a top-down approach, Hendrix et al. [12] analyzed available clinical data for Truvada to define concentration-prophylaxis relationships. However, this approach is naturally limited to PrEP candidates where sufficient clinical data already exists and is not able to disentangle the potency of the administered drugs from confounding factors. More mechanistic, bottom-up approaches integrate various host- and viral factors [13–18] to predict the probability of viral extinction. Despite their advantages, these approaches conventionally do not establish concentration-prophylaxis relations, or they are specific to particular drugs [17] or drug classes [18].

In this work, we will first analyze the drug-class specific relation between *in vitro* potency and PrEP efficacy and its dependency on the amount- and type of transmitted virus. Utilizing pharmacokinetic and pharmacodynamic data for all treatment-approved drugs, and simulating typical viral exposures during sexual contact, we will then screen all treatment-approved drugs for their PrEP utility and assess the sensitivity of the prophylactic endpoint with regard to uncertainties in viral dynamics parameters and with regard to variabilities in drug concentration, which can typically result from inter-individual metabolic differences or differences in medication adherence. Our central aim is to provide a tool to screen out drug candidates with a lack of- or uncertain prophylactic efficacy.

## Methods

Before HIV infection is irreversibly established, viral replication is highly stochastic [19], corroborated by the observation of a low transmission probability per exposure [20, 21] and a low number of founder viruses responsible for establishing infection [22–25]. The stochasticity can be explained by the order in which viral dynamics reactions occur: For example, when a single virus comes into proximity of target cells, it may either be cleared or it may infect the target cell which can eventually lead to systemic infection. In the current work, we will make use of branching process theory [26] to derive analytical solutions for the probability of viral extinction [13, 15], i.e. the probability to hit the absorbing state where all viral compartments go extinct. These solutions can be used directly to benchmark antivirals for their potential to prevent infection as exemplified in the current work, or they can be used to design efficient algorithms for the numerically *exact* simulation of complex prophylactic dosing regimen as proposed in a related article [27].

## Prophylactic efficacy

The infection probability  $P_I(Y_0)$  for some initial state  $Y_0$  is the complement of the extinction probability  $P_E(Y_0)$

$$P_I(Y_0) = 1 - P_E(Y_0), \quad (1)$$

where  $Y_0$  denotes the initial viral population in a replication enabling (target-cell) environment. Throughout the article we will use  $Y = [V, T_1, T_2]^T$ , i.e. the state of the viral dynamics is defined by infectious viruses, early- and productively infected cells as outlined below. The

extinction probability is defined by

$$P_E(Y_0) := \mathbb{P} \left( Y_t = \begin{bmatrix} 0 \\ 0 \\ 0 \end{bmatrix} \middle| Y_0 = \begin{bmatrix} V \\ T_1 \\ T_2 \end{bmatrix} \right) \quad (2)$$

for  $t \rightarrow \infty$ . In words, the probability that all viral compartments will eventually go extinct. The prophylactic efficacy  $\varphi$  then denotes the reduction in infection probability *per contact*,

$$\varphi = 1 - \frac{P_1(Y_0|D)}{P_1(Y_0|\emptyset)} \quad (\text{prophylactic efficacy}), \quad (3)$$

where  $P_1(Y_0|D)$  and  $P_1(Y_0|\emptyset)$  denote the infection probabilities in the presence- and absence of prophylactic drugs  $D$  respectively. The term  $P_1(Y_0|D)$  was computed using a mathematical model of the viral dynamics (below) and by mechanistically considering the *direct* effects of the distinct antivirals on viral replication whereas  $P_1(Y_0|\emptyset)$  is computed analogously, assuming the absence of drug  $D = 0$ .

### Drug-class specific *direct* effects on virus replication


**Virus replication dynamics.** We adopted the viral dynamics model described in [28, 29]. Although this model is a coarse representation of the molecular events happening during virus replication, it allows to accurately and mechanistically describe the effect of all existing antiretroviral drug classes on viral replication, as demonstrated in e.g. [30], and can be parameterized by available *in vitro* and *clinical* data. Unlike the original model [28, 29] we do not consider macrophages, motivated by the observation that transmitted viruses are not macrophage-tropic [31, 32] and in line with related modelling approaches [13, 14, 33–35]. The model is schematically depicted in Fig 1. The modelled viral replication cycle consists of free infectious viruses, uninfected T-cells, early infected T-cells ( $T_1$ ) and productively infected T-cells ( $T_2$ ). Early infected T-cells ( $T_1$ ) and productively infected T-cells ( $T_2$ ) denote T-cells prior- and after proviral integration respectively, where the latter produces virus progeny. The term  $T_u = \lambda_T/\delta_T$  denotes the steady state level of uninfected T-cells prior to virus challenge, where  $\lambda_T$  denotes the birth and  $\delta_T$  the death rate of uninfected T-cells. During the onset of infection the number viruses are relatively low and the number of uninfected T-cells is fairly unaffected by virus dynamics [33, 36]. Thus, for all computations, we consider the number of uninfected T-cells to be constant, in line with related approaches [14, 15]. The dynamics of the stochastic viral replication model after virus exposure are then defined by six reactions. In absence of antivirals  $\emptyset$  we have

$$a_1(\emptyset) = (CL + CL_T \cdot T_u) \cdot V \quad (\text{clearance of free virus; } V \rightarrow *) \quad (4)$$

$$a_2(\emptyset) = (\delta_{PIC} + \delta_{T_1}) \cdot T_1 \quad (\text{clearance of early infected cell; } T_1 \rightarrow *) \quad (5)$$

$$a_3(\emptyset) = \delta_{T_2} \cdot T_2 \quad (\text{clearance of late infected cell; } T_2 \rightarrow *) \quad (6)$$

$$a_4(\emptyset) = \beta \cdot T_u \cdot V \quad (\text{successful infection of a suscept. cell; } V \rightarrow T_1) \quad (7)$$



**Fig 1. Schematic of the HIV replication cycle and mechanism of interference by treatment-approved drug classes.** Free viruses are cleared by the immune system with a rate constant  $CL$ . Further, free viruses can be also cleared during unsuccessful T-cell infection  $CL_T$  through the destruction of essential viral components of the reverse transcription-, or pre-integration complex [37, 38]. The term  $\beta$  represents the lumped rate of infection of T-cells, including the processes of virus attachment to the cell, fusion and reverse transcription, leading to an early infected cell  $T_1$ , before proviral integration. Similarly, the term  $k$  denotes the rate by which early infected  $T_1$  cells are transformed into productively infected  $T_2$  cells, involving proviral integration and cellular reprogramming. The term  $N_T$  denotes the rate of production of infectious virus progeny by productively infected  $T_2$  cells. The rates  $\beta$ ,  $CL_T$ ,  $k$  and  $N_T$  may be modified by different antiretrovirals as indicated by bars (inhibition) and pointers with plus sign (drug-dependent increase). The terms  $\delta_{T_1} < \delta_{T_2}$  denote the rates of clearance of  $T_1$  and  $T_2$  cells respectively and  $\delta_{PIC}$  denotes the rate of intracellular destruction of the pre-integration complex. CRA: Co-receptor antagonists, RTIs: reverse transcriptase inhibitors, InIs: Integrase inhibitors, PIs: Protease inhibitors.

<https://doi.org/10.1371/journal.pcbi.1006740.g001>

$$a_5(\emptyset) = k \cdot T_1 \quad (\text{proviral integration; } T_1 \rightarrow T_2) \quad (8)$$

$$a_6(\emptyset) = N_T \cdot T_2 \quad (\text{production of infectious virus; } T_2 \rightarrow V + T_2), \quad (9)$$

with  $CL_T = \left(\frac{1}{\rho_{rev,\emptyset}} - 1\right) \cdot \beta$  in Eq (4) as outlined in [28] where  $\rho_{rev,\emptyset} = 0.5$  denotes the probability to successfully complete reverse transcription in the absence of inhibitors [37, 38]. Free viruses are cleared by the immune system with a rate constant  $CL$ . Further, free viruses can be also cleared during unsuccessful T-cell infection  $CL_T$  through the destruction of essential viral components of the reverse transcription-, or pre-integration complex intracellularly after the virus entered the cell [37, 38]. The term  $\beta$  represents the lumped rate of infection of T-cells, including the processes of virus attachment to the cell, fusion and reverse transcription, leading to an early infected cell  $T_1$ , before proviral integration. Similarly, the term  $k$  denotes the rate by which early infected  $T_1$  cells are transformed into productively infected  $T_2$  cells, involving proviral integration and cellular reprogramming. The term  $N_T$  denotes the rate of production of infectious virus progeny by productively infected  $T_2$  cells (*infectious burst size*). The terms  $\delta_{T_1} < \delta_{T_2}$  denote the rates of clearance of  $T_1$  and  $T_2$  cells respectively and  $\delta_{PIC}$  denotes the rate of intracellular destruction of the pre-integration complex. Parameters for the viral model are summarized in Table 1 and a mechanistic derivation of the dynamics from first principles is given in [28] (Supplementary Text therein).

**Class-specific direct drug effects.** The *direct* effect of drugs  $D \in \{RTI, CRA, InI, PI\}$  on their target process is typically modelled using the Emax-equation [39]

$$\eta_D(t) = \frac{D_t^m}{IC_{50}^m + D_t^m}, \quad (10)$$

where  $D_t$  is the target site concentration of the drug and the term  $IC_{50}$  and  $m$  denote the drug

concentration at which the targeted process is inhibited by 50% and a hill coefficient [40] respectively. In the current article we will assume that drug concentrations stay constant over the course of infection, which allows to study drug- and drug class specific properties with regard to prophylaxis. This assumption is overcome in related article [27], where pharmacokinetic inputs are explicitly considered to evaluate particular prophylactic dosing regimen.

**Reverse transcriptase inhibitors.** In the presence of reverse transcriptase inhibitors RTI the reaction propensities  $a_1$  and  $a_4$  are affected [28], i.e.

$$a_1(\text{RTI}) = \left( \text{CL} + \left( \frac{1}{\rho_{\text{rev},\emptyset}} - (1 - \eta_{\text{RTI}}) \right) \cdot \beta \cdot T_u \right) \cdot V \tag{11}$$

$$a_4(\text{RTI}) = (1 - \eta_{\text{RTI}}) \cdot \beta \cdot T_u \cdot V \tag{12}$$

where  $\eta_{\text{RTI}} \in [0, 1]$  follows from Eq (10). Eq (11) results from the specific action of reverse transcriptase inhibitors: they act only after irreversible fusion of viral particles and release of viral contents has occurred by halting reverse transcription, which increases the probability that essential viral constituents get cleared intracellularly preventing viral replication to progress. Thus, inhibition by RTIs can lead to an increase of cell-dependent clearance of viral particles as modelled in Eq (11) (see Supplementary Information of [28] for an explicit derivation). From the equations it becomes evident that the increase in cell-dependent clearance (effect on  $a_1$ ) matches the reduction in successful infection (effect on  $a_4$ ). The validity of this model has been assessed in [30].

**Other inhibitor classes.** Co-receptor antagonists (CRA) decrease the infection propensity  $a_4$  and  $a_1$ , whereas integrase inhibitors InI decrease  $a_5$  and protease inhibitors PI reduce  $a_6$  respectively by a factor  $(1 - \eta_D)$  [28]:

$$a_1(\text{CRA}) = \left( \text{CL} + (1 - \eta_{\text{CRA}}) \cdot \left( \frac{1}{\rho_{\text{rev},\emptyset}} - 1 \right) \cdot \beta \cdot T_u \right) \cdot V \tag{13}$$

$$a_4(\text{CRA}) = (1 - \eta_{\text{CRA}}) \cdot \beta \cdot T_u \cdot V \tag{14}$$

$$a_5(\text{InI}) = (1 - \eta_{\text{InI}}) \cdot k \cdot T_1 \tag{15}$$

$$a_6(\text{PI}) = (1 - \eta_{\text{PI}}) \cdot N_T \cdot T_2 \tag{16}$$

Note that unlike RTIs, CRAs decrease the adsorption of viral particles by cells, which does not *per se* lead to a cell-dependent clearance of viral particles as in the case of RTIs. InIs block proviral integration, affecting  $a_5$  and PIs prevent maturation, which lowers the amount of *infectious* viruses produced.

### Probability of virus extinction

For the ease of notation we introduce the unit vectors  $\hat{V}$ ,  $\hat{T}_1$  and  $\hat{T}_2$  which represent the states where only one infected compartment is present (either virus, early- or late infected cells)

$$\hat{V} = \begin{bmatrix} 1 \\ 0 \\ 0 \end{bmatrix}, \hat{T}_1 = \begin{bmatrix} 0 \\ 1 \\ 0 \end{bmatrix}, \hat{T}_2 = \begin{bmatrix} 0 \\ 0 \\ 1 \end{bmatrix} \tag{17}$$



**Table 1. Parameters generally used for the viral dynamics model.** Excerpt from [28], except for CL(naive), which assumed that virus clearance is smaller in virus-naive individuals compared to infected individuals, in line with [17, 72]. All parameters refer to the absence of drug treatment  $\emptyset$ . All parameters in units [1/day], except for  $\lambda$  [cells/day] and  $\beta$  [1/day/virus]. Parameter sensitivity was assessed in S2 Text.

Parameter	Value	Reference	Parameter	Value	Reference
$\lambda_T$	$2 \cdot 10^9$	[78]	$k$	0.35	[38]
$\delta_T, \delta_{T_1}$	0.02	[79]	$\beta$	$8 \cdot 10^{-12}$	[80]
$\delta_{T_2}$	1	[81]	$N_T$	670	[28, 79]
$\delta_{PIC}$	0.35	[38, 82]	CL(naive)	2.3	[14, 33]

<https://doi.org/10.1371/journal.pcbi.1006740.t001>

While free virus is typically transmitted, our framework also allows to study prophylactic efficacy for arbitrary initial states. Using the notation above, any state of the system can be expressed as a linear combination of the unit vectors above. For example,  $5 \cdot \hat{V} \oplus 3 \cdot \hat{T}_1 \oplus 12 \cdot \hat{T}_2$  denotes the state where we have 5 viruses, 3 early infected cells and 12 late infected cells. In S1 Text we provide a detailed derivation of infection/extinction probabilities after viral exposure. Herein, we will provide a sketch of the central idea.

Starting from a single virus  $Y_0 = \hat{V}$ , we can write the Chapman-Kolmogorov equation:

$$P_E(Y_0 = \hat{V}) = \sum_{n=0}^{\infty} \mathbb{P}(Y_r = n \cdot \hat{V} | Y_0 = \hat{V}) \cdot P_E(Y_r = \hat{V})^n. \tag{18}$$

In words, the extinction probability  $P_E(Y_0 = \hat{V})$  is given by the probability that  $n$  viruses are produced in a single replication cycle  $r$ ,  $\mathbb{P}(Y_r = n \cdot \hat{V} | Y_0 = \hat{V})$ , and that all of these viruses eventually go extinct, considering all possible values of  $n$ . Herein we assumed *statistical independence*, i.e.  $P_E(Y_r = n \cdot \hat{V}) = P_E(Y_r = \hat{V})^n$ . Furthermore, the extinction probabilities for parent- and progeny virus are identical when the inhibitor efficacy is constant, i.e.  $P_E(Y_0 = \hat{V}) = P_E(Y_r = \hat{V})$ . Next, we construct the embedded Markov chain [26] corresponding from the continuous-time Markov jump model depicted in Fig 1 with parameters in Table 1 (details in S1 Text). This allows to derive algebraic formulas for  $\mathbb{P}(Y_r = n \cdot \hat{V} | Y_0 = \hat{V})$ ,  $n = 0 \dots \infty$ . Substituting these into Eq (18), rearranging and solving for  $P_E(Y_0 = \hat{V})$  yields a quadratic formula. Solving the quadratic formula, and using  $P_E(\cdot) = 1 - P_I(\cdot)$  we derive analytical solutions for the infection probabilities after exposure to a single virus  $\hat{V}$ , early-  $\hat{T}_1$  and late infected cell  $\hat{T}_2$ :

$$P_I(Y_0 = \hat{V}) = \max\left(0, \frac{a_4(D)}{a_1(D) + a_4(D)} \cdot \frac{a_5(D)}{a_2 + a_5(D)} \left(1 - \frac{1}{R_0(D)}\right)\right) \tag{19}$$

$$P_I(Y_0 = \hat{T}_1) = \max\left(0, \frac{a_5(D)}{a_2 + a_5(D)} \cdot \left(1 - \frac{1}{R_0(D)}\right)\right) \tag{20}$$

$$P_I(Y_0 = \hat{T}_2) = \max\left(0, 1 - \frac{1}{R_0(D)}\right). \tag{21}$$

where  $R_0(D)$  denotes the basic reproductive number, i.e. the average number of viruses produced from a single founder virus [41] in a single replication cycle under the action of drug  $D$ . Using our model we have  $R_0(D) = \frac{a_4(D)}{a_1(D) + a_4(D)} \cdot \frac{a_5(D)}{a_2 + a_5(D)} \cdot \frac{a_6(D)}{a_3}$ . The first solution  $P_I(\cdot) = 0$  of

Eqs (19)–(21) are valid in the regimen where  $R_0(D) \leq 1$ , i.e. in the regimen where extinction is certain. The second solution describes the case where infection may occur, i.e.  $R_0(D) > 1$ . The pre-terms in the second solution of Eqs (19) and (20) denote the bottlenecking probabilities that a late-infected, virus producing cell is reached, starting from a free virus (Eq (19)) or starting from an early infected cell (Eq (20)) respectively.

We can assume *statistical independence* during the onset of infection (i.e. competition for target cells is negligible) as noted before. Hence, for any given combination of free virus, early-stage infected cell and late-stage infected cell the extinction probability is given by

$$P_E \left( Y_0 = \begin{bmatrix} V \\ T_1 \\ T_2 \end{bmatrix} \right) = \left( P_E(Y_0 = \widehat{V}) \right)^V \cdot \left( P_E(Y_0 = \widehat{T}_1) \right)^{T_1} \cdot \left( P_E(Y_0 = \widehat{T}_2) \right)^{T_2}, \quad (22)$$

where the exponents  $V$ ,  $T_1$  and  $T_2$  denote the number of free virus, early- and late-stage infected cells present and where we notice that  $P_E(\cdot) = 1 - P_I(\cdot)$ .

### Virus exposure model

Initial viral exposure after sexual intercourse occurs at tissue sites typically not receptive for establishing and shedding HIV infection (e.g. mucosal tissues). Hence, the virus needs to pass several bottlenecks and physiological barriers to reach a replication enabling (target-cell) environment where infection can be established and from where it can shed systemically [42]. To determine realistic inoculum sizes after sexual exposure to HIV, we previously developed a data-driven statistical model linking plasma viremia in a transmitter to the initial viral population  $Y_0$  in a replication-enabling environment [18] (Supplementary Note 4 therein for details). Herein, we used the ‘exposure model’ to compute drug efficacy estimates after homosexual exposure presented in section *Prophylactic efficacy of treatment-approved antiretrovirals*. In brief, this ‘exposure model’ was developed to capture key clinical observations: (i) the average HIV transmission probabilities per exposure as reported in [20, 21, 43]. (ii) the fact that viral loads in the untreated transmitter population are approximately log-normal distributed [18, 44–46] ( $\mu = 4.51$ ,  $\sigma = 0.98$ ) and (iii) the observation that the plasma viremia in the transmitter is the most dominant factor determining HIV transmission [44, 47–49]. More specifically, it was reported that each 10-fold increase in the transmitter’s viral load increases the transmission probability per coitus by approximately 2.45-fold [47] (similar values confirmed in [49]). The aforementioned clinical observations can be summarised in the formula below:

$$\bar{P}_{\text{trans}} = \int_{v=0}^{\infty} P(\text{VL} = v) \cdot \left( \sum_{n=0}^{\infty} P(Y_0 = n \cdot \widehat{V} | \text{VL} = v) \cdot P_I(Y_0 = n \cdot \widehat{V}) \right) \quad (23)$$

where  $\bar{P}_{\text{trans}}$  is the average transmission probability per exposure/coitus (given in (i)),  $P(\text{VL} = v)$  is the probability density of viral load in the donor (log-normal distributed, given in (ii)),  $P_I(Y_0 = n \cdot \widehat{V})$  is the infection probability when  $n$  viruses reach a replication enabling site (computed from the virus dynamics model above with  $P_I(Y_0 = \widehat{V}) \approx 0.0996$ ) and  $P(Y_0 = n \cdot \widehat{V} | \text{VL} = v)$  denotes the ‘exposure model’ (the probability that  $n$  viruses reach a replication-enabling compartment after viral exposure from a transmitter with virus load  $v$ ). For the ‘exposure model’, we assumed a binomial distribution

$$P(Y_0 = n \cdot \widehat{V} | \text{VL} = v) = \binom{\lceil v^m \rceil}{n} \cdot r^n \cdot (1 - r)^{\lceil v^m \rceil - n} \quad (24)$$



where  $m = \log_{10}(2.45)$  is given by (iii) [47] and the *success probability*  $r$  was estimated in a previous work [18] (Supplementary Note 4 therein), e.g.  $r_{\text{homosexual}} = 3.71 \cdot 10^{-3}$  for homosexual exposure. However, the model can be adapted to the different exposure types (e.g. heterosexual, needle-stick, etc . . .). In this model, the *success probability*  $r$  summarises both the extent of local exposure, as well as the probability of passing all bottlenecking physiological barriers and reaching a replication enabling target cell compartment. Lastly, in line with Keele et al. [22], we observed that if infection occurs in our model it is established by a very low number of viruses after homosexual contact and usually by a single founder virus after heterosexual contact.


## Results

### Relation between direct effects and prophylactic efficacy

Drug-specific inhibition of viral replication can be studied *in vitro*, for example in single-round turnover experiments [40] or even more mechanistically using enzymatic assays in conjunction with appropriate mathematical models [50]. Since the infection risk per exposure is already low in untreated individuals [20, 21], exploring the prophylactic efficacy (reduction in infection risk) in the clinic is difficult, requiring very long (several years) clinical trials with many individuals ( $N > 1000$ ) to achieve statistically evaluable results. Systematic evaluation of concentration-effect relations is not feasible in this context, notwithstanding ethical concerns.

We wanted to gain a deeper insight how *in vitro* measurable direct drug efficacy  $\eta$  translates into prophylactic efficacy  $\varphi$  (reduction in infection probability per exposure) in a drug-class specific manner. Particularly, since different antiviral drug classes inhibit distinct stages in the HIV replication cycle, we wanted to elucidate how these different mechanisms of action affect prophylaxis. We combined Eqs (11)–(16) with Eqs (19)–(21) into Eq (3) to predict prophylactic efficacy. When relating *direct* drug effects  $\eta$  to prophylactic efficacy  $\varphi$  we observed striking drug-class specific differences as illustrated in Fig 2. Using parameters from Table 1 we found that the prophylactic efficacy  $\varphi$  may be less than predicted by *in vitro* measurable direct drug effects  $\eta$ . The sole exception are reverse transcriptase inhibitors (RTI) in case of exposure to a single virus particle  $Y_0 = \hat{V}$  where the two measures of drug efficacy coincide. While the prophylactic efficacy after exposure to a single virus are moderately less than the direct effects of co-receptor antagonists CRA and integrase inhibitors InI respectively (Fig 2A), there is a profound difference for protease inhibitors, which do not seem to reduce HIV transmission unless their direct efficacy  $\eta$  exceeds  $\approx 95\%$ . Interestingly, a similar observation using a different mathematical model and only distinguishing RTIs and PIs has been made by Conway et al. [13].

While HIV-transmission typically occurs after exposure to free virus, it is still useful to study the prophylactic efficacy of distinct drug classes in the hypothetical case when infected cells were present in the exposed individual. A realistic example for this scenario is post-exposure prophylaxis (PEP): During PEP, drugs are taken shortly *after* virus exposure and initial viral replication steps may have taken place generating early- or late infected cells. As can be seen in Fig 2B and 2C, the prophylactic efficacy of all drugs profoundly deteriorates compared to their direct effects, i.e. only very effective (in terms of  $\eta$ ) drugs may prevent systemic infection once cells become infected in the exposed individual. An exception are integrase inhibitors: their prophylactic efficacy  $\varphi$  is moderately less than their direct effect  $\eta$  (panel B) if only early infected cells  $T_1$  (before proviral integration) were present. Thus, while the prophylactic efficacy of all other drug classes is profoundly less than their direct effects once infected cells emerged, integrase inhibitors may still potently prevent infection. An intuitive explanation for the deterioration of prophylactic efficacy can be made in terms



**Fig 2. Relation between direct drug effect and prophylactic efficacy.** The relation between direct drug effect  $\eta$  and prophylactic efficacy  $\phi$  (reduction in infection) is shown for different drug classes utilizing the viral model depicted in Fig 1 with parameters stated in Table 1. Panel A: Relation between  $\eta$  and  $\phi$  when a single virus  $Y_0 = \hat{V}$  reached a replication-enabling compartment in the virus-exposed individual. Panel B: Relation between  $\eta$  and  $\phi$  when a single early infected cell  $Y_0 = \hat{T}_1$  or (panel C) a late infected T-cell  $Y_0 = \hat{T}_2$  reached a replication-enabling compartment. Solid red lines: CRAs, solid green line: RTIs, dashed blue line: InI, dashed purple line: PIs.

<https://doi.org/10.1371/journal.pcbi.1006740.g002>

of changes in drug-target stoichiometry: For example, after exposure to a single virus  $\hat{V}$ , drugs from the classes of CRAs, RTIs and InIs need to block a single reaction to foster viral extinction. For PIs however, the same is only achieved if maturation of the entire viral progeny is inhibited (possibly hundreds of particles). Similarly, when considering a single early infected cell  $\hat{T}_1$ , CRAs and RTIs can only prevent further viral expansion *after* viral progeny has emerged. Subsequently, for each viral particle (possibly hundreds) the respective target processes (receptor binding, reverse transcription) need to be blocked by the inhibitors. Along the same lines of argumentation it is also evident that prophylactic efficacy is generally more favourable in the case of PrEP, compared to post-exposure prophylaxis (PEP), where initial viral replication may have occurred.

### ***In vitro* drug potency may overestimate PrEP potency**

*In vitro* measured drug potency  $IC_{50}$ ,  $IC_{90}$  usually guides the design of PrEP trials [51]. In particular, dosing regimen are designed so that the majority of individuals achieve drug levels just above the 90% inhibitory concentrations  $IC_{90}$ . However, it has never been rigorously investigated whether these ‘target concentrations’ are sufficient to provide 90% protection against HIV infection. Integrating Eq (10) into Eqs (11)–(16), (19) and (3) allows to predict the concentration-prophylaxis profile for different HIV-1 inhibitor classes. Rearranging this composite equation reveals how *in vitro* measured drug potency  $IC_{50}$ ,  $IC_{90}$  can be translated into prophylactic potency (50% and 90% reduction in infection risk,  $EC_{50}$  and  $EC_{90}$ , respectively), guiding clinical trial design. The derived analytical expressions for the prophylactic efficacy (reduction in infection risk) indicate that the shape of the concentration-prophylaxis profile varies considerably for different HIV-1 inhibitor classes with important consequences for their prophylactic endpoints (% reduction in HIV transmissibility).

After exposure to a single virion  $Y_0 = \hat{V}$ , the overall shape of the concentration-prophylaxis profile for co-receptor antagonists (CRAs), reverse transcriptase inhibitors (RTIs) and integrase inhibitors (InIs) is a classical Emax equation (the equation of choice for evaluating

concentration-effect relations), see [S1 Text](#) for derivation.

$$\varphi(\widehat{V}) = \frac{R_0(\emptyset)}{R_0(\emptyset) - 1} \cdot \frac{D^m}{IC_{50}^m \left(\frac{1}{\vartheta}\right) + D^m} \stackrel{R_0(\emptyset) \gg 1}{\approx} \frac{D^m}{EC_{50}^m + D^m} \quad (\text{CRA}) \quad (25)$$

$$\varphi(\widehat{V}) = \frac{R_0(\emptyset)}{R_0(\emptyset) - 1} \cdot \frac{D^m}{IC_{50}^m + D^m} \stackrel{R_0(\emptyset) \gg 1}{\approx} \frac{D^m}{EC_{50}^m + D^m} \quad (\text{RTI}) \quad (26)$$

$$\varphi(\widehat{V}) = \frac{R_0(\emptyset)}{R_0(\emptyset) - 1} \cdot \frac{D^m}{IC_{50}^m \left(\frac{1}{\vartheta}\right) + D^m} \stackrel{R_0(\emptyset) \gg 1}{\approx} \frac{D^m}{EC_{50}^m + D^m} \quad (\text{InI}) \quad (27)$$

where  $D$  denotes the concentration of the drug in the blood plasma,  $m$  is a slope parameter and  $IC_{50}$  denotes the plasma concentration of the drug that inhibits the targeted process (co-receptor binding, reverse transcription or proviral integration) by 50 percent. This parameter can typically be measured *in vitro*, e.g. using single-round turnover experiments [40] and is stated in [Table 2](#) for various drugs. Parameters  $v = \frac{CL \cdot \rho_{rev, \emptyset}}{CL \cdot \rho_{rev, \emptyset} + \beta \cdot T_{in}} < 1$  and  $\vartheta = \frac{\delta_{PIC} + \delta_{T_1}}{\delta_{PIC} + \delta_{T_1} + k} < 1$  denote the respective probabilities, in the absence of drugs, that the virus is eliminated before entering a host cell, and that essential virus compartments get cleared intracellularly after reverse transcription and before provirus integration. The parameter  $EC_{50}$  denotes the plasma concentration of the drug that decreases the probability of infection by 50%, i.e. the *prophylactic potency* of the drug.  $R_0(\emptyset)$  denotes the basic reproductive number in the absence of drugs, i.e. the average number of viruses produced from a single founder virus [41] in a single replication cycle when no antivirals were present ( $R_0(\emptyset) \approx 67$  according to the utilized model). When the target cell density is sufficiently high (herein considered as a target cell environment), we have  $R_0(\emptyset) \gg 1$  and hence the left-side scaling factor in Eqs (25)–(27) will be close to one,  $R_0(\emptyset)/(R_0(\emptyset) - 1) \approx 1$ . An analysis with low target cell densities is provided in [S2 Text](#).

In case of exposure to a single virus particle  $\widehat{V}$ , the slope parameters in the right-most equations coincide with the slope parameter for the respective drug-targeted process  $m$  (Eq (10)), stated in [Table 2](#). Notably, for RTIs, we have  $EC_{50} \approx IC_{50}$ , i.e. the drugs potency measured *in vitro* in single-round turnover experiments [40] directly translates into its potency to prevent infection. Using parameters from [Table 1](#) we observe  $EC_{50} > IC_{50}$  for CRAs and InIs, i.e. compared to their *in vitro* potency, they are less potent in preventing infection. This is largely due to the respective factors  $\vartheta^{-1}, v^{-1} > 1$ , compare [Fig 3A–3C](#). For InIs this observation is robust across a broad range of parameter values, as shown in [S2 Text](#). Consequently, for InIs, higher concentrations are required to prevent infection than suggested after conducting the respective *in vitro* experiments. For CRAs, predictions are parameter dependent, [S2 Text](#). Rearranging Eqs (25)–(27) allows to directly compute the drug concentration that prevents infection with  $x$  percent probability (the  $EC_x$ ) from the corresponding *in vitro* 50% inhibitory concentration  $IC_{50}$  (derivations in [S3 Text](#)): In case of exposure to a single virus particle we get

$$EC_x = IC_{50} \cdot \left( F \cdot \frac{x}{100 \cdot C - x} \right)^{1/m}, \quad (28)$$

where  $EC_x$  is the drug concentration that achieves  $x$  percent of prophylactic efficacy and the

**Table 2. Pharmacodynamic and pharmacokinetic parameters.** IC<sub>50</sub> [nM] and *m* [unit less] values are available from single turnover experiments in primary peripheral blood mononuclear cells supplemented with 50% human serum from Shen et al. [40], Laskey et al. [92] (DTG) and Jilek et al. [93] (MVC). Because some compounds are highly protein bound, IC<sub>50</sub> values had to be adjusted for protein binding as outlined in the S5 Text. Indicated values are after protein adjustment. IC<sub>50</sub> values are reported to be log normal distributed and *m* values to be normal distributed [40, 93] with respective coefficients of variation CV = 100 · σ/μ [%]. Parameters C<sub>min</sub> and C<sub>max</sub> refer to the minimum and maximum concentrations in [nM] during chronic administration using the standard dosing regimen, taken from Shen et al. [40] except those for DTG [94], RPV [95] and MVC [96] (150mg twice daily). t<sub>1/2</sub>—half life of the drug in [hr], f<sub>b</sub>—fraction of the drug bound to plasma proteins in [%]. \*These values were fixed to the typical parameter distributions observed for all other compounds. °Parameters were taken from Drug Bank when available <https://www.drugbank.ca/>, accession numbers: DB04835, DB00625, DB00238, DB00705, DB08864, DB06817, DB09101, DB08930, DB01072, DB00701, DB01264, DB00224, DB00220, DB00932 or PubChem <https://pubchem.ncbi.nlm.nih.gov>, id: 92727. When parameters were not readily available in these databases, parameters were obtained from the indicated literature source. MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirine, ETR -etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir, DTG -dolutegravir, ATV -atazanavir, APV -amprenavir, DRV -darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir.

Class	Name	IC <sub>50</sub>	(CV)	<i>m</i>	(CV)	C <sub>min</sub>	C <sub>max</sub>	f <sub>b</sub>	t <sub>1/2</sub>
CRA	MVC	5.06	(290)	0.61	(27.9)	45	557	76°	14°
RTI	EFV	10.7	(16.7)	1.69	(4.73)	5630	12968	99.4 [83]	40°
RTI	NVP	116	(31.2)	1.55	(9.68)	10883	25153	60°	45°
RTI	DLV	336	(44.7)	1.56	(11.5)	10672	27134	98 [84]	5.8°
RTI	ETR	8.59	(16.3)	1.81	(12.7)	688	1617	99.9 [85]	35 [86]
RTI	RPV	7.73	(17.9)	1.92	(10.4)	177	470	99.1°	44.5°
InI	RAL	25.5	(12.1)	1.1	(4.55)	203	3996	83°	9°
InI	EVG	55.6	(43.8)	0.95	(4.21)	301	1661	99°	8.7°
InI	DTG	89.0	(25.3 <sup>+</sup> )	1.3	(15.4 <sup>+</sup> )	2918	8471	98.9°	14.5 [87]
PI	ATV	23.9	(11.8)	2.69	(10.4)	899	6264	86 [88]	7°
PI	APV	262	(12.6)	2.09	(6.70)	2870	14319	90°	7.1°
PI	DRV	45.0	(21.6)	3.61	(8.86)	5081	14783	95 [85]	15°
PI	IDV	130	(11.0)	4.53	(7.94)	1827	12508	60 [89]	1.8°
PI	LPV	70.9	(20.1)	2.05	(5.85)	8757	15602	99 [60]	2.5 <sup>b</sup>
PI	NFV	327	(26.8)	1.81	(12.7)	2285	5104	98°	3.5°
PI	SQV	88.0	(9.7)	3.68	(6.25)	897	13282	97 [90]	3.9 [91]
PI	TPV	483	(18.0)	2.51	(14.3)	35598	77585	99.9°	5°

<https://doi.org/10.1371/journal.pcbi.1006740.t002>

term  $F \geq 1$  is a drug class specific factor


$$F = \begin{cases} \left( \text{CL} + \frac{\beta \cdot T_u}{\rho} \right) / \text{CL}, & \text{for CRA} \\ 1, & \text{for RTI} \\ 1/\vartheta, & \text{for InI.} \end{cases} \quad (29)$$

and

$$C := \frac{R_0(\varnothing)}{R_0(\varnothing) - 1} \approx 1, \quad (30)$$

if  $R_0(\varnothing) \gg 1$ . Importantly, when exposure to multiple viruses occurs, the concentration-prophylaxis profile is no longer an Emax equation for any inhibitor class, Fig 3A–3C. Furthermore, the slope parameter increases and the EC<sub>50</sub> may exceed the *in vitro* measurable IC<sub>50</sub> value. At large inoculum, the corresponding profiles become switch-like. For protease inhibitors (PIs), we derive a power function to describe their prophylactic efficacy (mechanistic derivation in S1 Text):

$$\varphi(\hat{V}) = \frac{1}{R_0(\varnothing) - 1} \cdot \frac{D^m}{\text{IC}_{50}^m} = C \cdot \frac{D^m}{\text{IC}_{50}^m} \quad (\text{PI}) \quad \text{for } 0 \leq \varphi \leq 1, \quad (31)$$



**Fig 3. Shape of the concentration-prophylaxis profile.** Colored lines depict the concentration-prophylaxis profile for an average drug class-specific slope parameter  $\bar{m}$  in Eq (10). Solid colored line for an inoculum of one virus  $Y_0 = \hat{V}$  and dashed colored line for an inoculum of  $Y_0 = 100 \cdot \hat{V}$ . Shaded areas indicate the concentration-prophylaxis profile for the smallest  $m_{\min}$  and largest class-specific slope parameter  $m_{\max}$  for the respective drug class as indicated in Table 2. **A:** Co-receptor antagonists. Currently only one co-receptor antagonist, maraviroc, is approved. We use  $\bar{m} = m_{\min} = 0.61$  and also plot  $m_{\max} = 1$  as a reference. **B:** Non-nucleoside reverse transcriptase inhibitors (NNRTIs);  $\bar{m} = 1.71$ ,  $m_{\min} = 1.55$  and  $m_{\max} = 1.92$ . Nucleoside reverse transcriptase inhibitors (NRTI) have been analyzed in [18]. **C:** Integrase inhibitors,  $\bar{m} = 1.12$ ,  $m_{\min} = 0.95$  and  $m_{\max} = 1.3$ . **D:** Protease inhibitors;  $\bar{m} = 2.87$ ,  $m_{\min} = 1.81$  and  $m_{\max} = 4.53$ . Utilized virus dynamics parameters are stated in Table 1.

<https://doi.org/10.1371/journal.pcbi.1006740.g003>

where  $C \ll 1$  is a constant. Moreover, for realistic (large)  $R_0(\emptyset) \gg 3$  their plasma concentration has to exceed their  $IC_{50}$  to decrease the probability of infection by at least 50%, Fig 3D. Similarly, we can rearrange the equation above and obtain

$$EC_x = IC_{50} \cdot \left(G \cdot \frac{x}{100}\right)^{1/m}, \tag{32}$$

for the exposure to a *single virus*, where  $G := R_0(\emptyset) - 1$ . Again, in case of exposure to multiple viruses, the slope parameter and  $EC_{50}$  increase, making the prophylactic efficacy of PIs exhibiting a switch-like behaviour as can be seen in Fig 3D. This switch-like behaviour makes the prophylactic use of PIs vulnerable to non-adherence, as well as general variations in concentrations (e.g. pharmacokinetics, inter-individual variability), and the prophylactic efficacy with these inhibitors may alternate between zero- or complete protection.


### Prophylactic efficacy of treatment-approved antivirals

The combination of the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir (Truvada) is the only intervention approved for pre-exposure prophylaxis (PrEP). According to our previous estimates [18], Truvada provides 96% protection in fully adherent individuals, which is in line with clinical estimates of 86-100% protection in the IPERGAY study [1], 58-96% in the PROUD study [2] and 96% in the Partners PrEP OLE study in apparently highly adherent individuals. The VOICE [3] and FEM-PrEP [52] studies indicated that Truvada may not prevent infection in poorly adherent individuals.

Currently, a number of drugs are under investigation for PrEP repurposing [6]. Notably, all currently investigated compounds are patent-protected and may not be affordable in resource-constrained countries hit hardest by the epidemic. In this work, we wanted to unselectively assess the utility of treatment-approved antivirals for prophylaxis and to assess whether currently neglected (patent-expired) compounds may be cost-efficient alternatives to be further explored in non-profit prophylaxis programmes.

We utilized comprehensive sets of drug-specific pharmacodynamic- and pharmacokinetic parameters (Table 2) to parameterize Eq (10) and to predict the prophylactic efficacy of treatment approved CRAs, non-nucleoside reverse transcriptase inhibitors (NNRTIs), InIs and PIs at clinically relevant concentration ranges (the class of NRTIs have been analyzed in earlier work [18]). Moreover, we sampled the extent of viral exposure (number of viruses transmitted and reaching a replication-enabling compartment; Eq (22)) from a previously parameterized distribution [18] that accurately reflects transmitter virus loads and drug-free infection probabilities after sexual contact. The resultant benchmark is depicted in Fig 4. Fig 4 allows for an initial screen of the utility of the various drugs for oral PrEP. Most analyzed drugs, except for maraviroc (MVC), raltegravir (RAL), elvitegravir (EVG) and nelfinavir (NFV), potentially prevent infection at concentrations ranges typically encountered in fully adherent individuals during treatment (range between minimum- to maximum concentration,  $[C_{\min}; C_{\max}]$ ). During prophylaxis, adherence to the dosing regimen is a major problem and we thus consider a lower bound concentration that would arise if the drug had not been taken for three days prior to exposure  $C_{\text{low}}$  (thin dashed vertical line in Fig 4) to emphasise a 'pharmacokinetic safety margin' in case of poor adherence. Numerical values for the computed maximum prophylactic efficacy and the efficacy at the lower bound concentrations are reported in Table 3 alongside with estimated  $EC_{50}$  and  $EC_{90}$  values. While in Table 3 we report the  $EC_{50}$  and  $EC_{90}$  values after challenge with a single virus  $\hat{V}$ , the corresponding values after virus challenges sampled from the distribution for homosexual exposure Eq (24) were almost identical, see S4 Text for a comparison. Our simulations indicate a residual risk of infection for most analyzed drugs. Notably, most protease inhibitors may confer anything from none- to absolute protection within relevant concentration ranges,  $[C_{\text{low}}; C_{\max}]$ , which highlights a severe limitation to their PrEP use in the context of poor adherence or pharmacokinetic (intra-/inter individual) variability. An exception among this rule is darunavir (DRV), which is predicted to be almost fully protective for the entire concentration range.





**Fig 4. Drug specific prophylactic efficacy.** Solid and dashed colored lines depict the concentration-prophylaxis profile for the individual drugs. The solid lines represent the concentration-prophylaxis profiles and light and dark grey areas indicate the quartile ranges and 5-95% ranges of the concentration-prophylaxis profile, considering uncertainty in pharmacodynamic parameters (Table 2) and the distribution of viral inoculum sizes after homosexual exposure to HIV using the virus exposure model (Methods section and [18]). Maximum clinically achievable concentrations  $C_{max}$  for chronic oral administration of the standard dosing regimen and a lower bound concentration  $C_{low}$  that would be achieved if the last dose had been taken three days prior to virus

exposure are marked by thick and thin vertical black dashed lines respectively. For IDV, LPV, NFV and SQV  $C_{low}$  falls below the range of the x-axis. Downward pointing arrows indicate minimum (pre-dose) concentrations achieved for standard regimen in *adherent* individuals as reported in [40], [96] and [95]. MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirdine, ETR -etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir, DTG -dolutegravir, ATV -atazanavir, APV -amprenavir, DRV -darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir. \* recently or currently tested for PrEP.

<https://doi.org/10.1371/journal.pcbi.1006740.g004>

Of the analyzed non-PI drugs, the NNRTIs efavirenz (EFV), nevirapine (NVP), etravirine (ETR) and rilpivirine (RPV) are extremely potent with regard to prophylaxis: These drugs prevent infection, even when the drug had not been taken for three consecutive days, Table 3. Notably, NVP and EFV are patent-expired and may represent suitable candidates for use in resource-constrained settings (price per day  $\approx$  0.1US\$). The co-receptor antagonist maraviroc (MVC) and the integrase inhibitor dolutegravir (DTG) retain some prophylactic efficacy (50 and 72% respectively) at lower bound concentrations  $C_{low}$ . The CRA maraviroc (MVC), the NNRTI rilpivirine (RPV) and the InI raltegravir (RAL) are currently investigated for use as PrEP compounds (long-acting injections of RPV and RAL; oral- or topical application of MVC). In our simulations the predicted PrEP efficacy of these drugs would drop to 8% (RAL) and 50% (MVC) when the drug had not been taken for three consecutive days prior to virus exposure. Notably, RPV remained 100% effective.

Lastly, we want to note that our predictions are based on viral dynamics parameters that may under-predict prophylactic efficacy, as indicated in S2 Text. The main purpose of this modelling study was to rule out drug candidates, based on lack-off- or uncertain- prophylactic

**Table 3. Prophylactic efficacy and sensitivity to incomplete adherence.** The table shows the prophylactic efficacy (% reduction in infection probability) of all investigated drugs at their respective maximum achievable drug concentrations after chronic oral administration of the standard regimen and its efficacy at a concentration level that would be reached if the last dose had been taken least three days prior to virus exposure  $C_{low} = C_{min} \cdot e^{-2 \cdot 24 \cdot k_e}$ , with  $k_e = \ln(2)/t_{1/2}$  and half-lives  $t_{1/2}$  reported in Table 2. The 5-95% range of these estimates are shown in brackets and consider uncertainty in pharmacodynamic parameters  $IC_{50}$ ,  $m$  and variability in virus exposure after homosexual contact, according to the ‘virus exposure model’ (Methods section and Duwal et al. [18]). The last two columns show the  $EC_{50}$  and  $EC_{90}$  in the case when an individual was exposed to a single virus  $\hat{V}$ . MVC -maraviroc, EFV -efavirenz, NVP -nevirapine, DLV -delavirdine, ETR -etravirine, RPV -rilpivirine, RAL -raltegravir, EVG -elvitegravir, DTG -dolutegravir, ATV -atazanavir, APV -amprenavir, DRV -darunavir, IDV -indinavir, LPV -lopinavir, NFV -nelfinavir, SQV -saquinavir, TPV -tipranavir. \* currently investigated for PrEP.

drug	prophylactic efficacy $\phi$ [%]				$EC_{50}(\hat{V})$	$EC_{90}(\hat{V})$
	$\phi(C_{max})$		$\phi(C_{low})$		[nM]	[nM]
MVC*	96.10	(74.11;100)	50.12	(18.63;85.42)	11.45	349.63
EFV	100	(100;100)	100	(100;100)	10.55	36.23
NVP	100	(100;100)	100	(100;100)	114.06	438.06
DLV	100	(100;100)	3.38	(0.88;10.19)	329.50	1254.58
ETR	100	(100;100)	100	(100;100)	8.45	26.75
RPV*	100	(100;100)	100	(99.02;100)	7.61	22.55
RAL*	100	(100;100)	8.15	(6.32;10.23)	45.40	302.36
DTG*	100	(99.03;100)	72.12	(57.77;84.85)	145.18	722.23
EVG	94.61	(89.02;97.97)	6.96	(3.66;12.49)	108.66	976.25
ATV	100	(100;100)	0.08	(0.04;0.15)	87.44	108.79
APV	100	(100;100)	0.01	(0.01;0.03)	1394.96	1848
DRV*	100	(100;100)	100	(100;100)	118.32	139.24
IDV	100	(100;100)	0	(0;0)	280.80	319.71
LPV	100	(100;100)	0	(0;0)	389.69	519.09
NFV	100	(64.01;100)	0	(0;0)	2253.66	3118.34
SQV	100	(100;100)	0	(0;0)	227.29	266.66
TPV	100	(100;100)	0	(0;0.02)	1944.89	2458.09

<https://doi.org/10.1371/journal.pcbi.1006740.t003>

efficacy. While some drugs' prophylactic efficacy might be under-predicted, this *conservative* choice of parameters provides a more solid scientific basis for the remaining candidates that are predicted to be potent.

## Discussion

Our intent was to develop a tool to screen out unsuitable candidates for PrEP based on unfavourable pharmacokinetic and pharmacodynamic characteristics. Clearly, the attributes which make any compound favourable extend beyond PK/PD, and critically also depend on tolerability, ease of dosing, cost and acceptability. Nevertheless, screening antiretroviral agents based on their intrinsic antiviral activity, mode of action, duration of efficacy beyond the dosing interval, and tolerance for missed dosing is a logical starting point when assessing potential candidates for PrEP.

Strikingly, we observed that *in vitro* measured drug potency may over-estimate PrEP potency in a drug-class specific manner. For all non-RTI drugs dosing schedules in clinical trials may have to be adjusted accordingly to reach the desired prophylaxis endpoints (% protection). We provide an easy-to-use software tool to determine the corresponding target concentrations ([www.systems-pharmacology.org/prep-predictor](http://www.systems-pharmacology.org/prep-predictor)).

For non-PI drugs, we observed a more graded relationship between their prophylactic efficacy and drug concentrations. At low virus inoculum sizes, the slope of their concentration-prophylaxis profile is largely determined by the slope coefficient that describes their direct effects [40]. Notably, for PIs we observed a very steep concentration prophylaxis profile, suggesting that within clinically relevant ranges for oral PrEP (Fig 4) their efficacy is likely to switch between zero- and complete protection, in an 'either-or' scenario. This characteristic renders PIs particularly vulnerable to poor adherence and drug-drug interactions. An intuitive explanation for this steep concentration-prophylaxis profile of PIs (power function in Eq (31)) is based on its unfortunate drug-to-target stoichiometry: A single late infected cell  $T_2$  produces hundreds of infectious viruses on average (using parameters from Table 1  $a_6/a_3 = 670$ ) and a PI needs to prevent all of them from becoming infectious to fully prevent infection. By contrast, all other compounds only need to prevent a single viral entity from progressing, explaining the proportionality to the EMAX equation seen in Eqs (25)–(27).

By screening all treatment-approved antivirals for their PrEP utility, we predicted that efavirenz (EFV), nevirapine (NVP), etravirine (ETR), rilpivirine (RPV) and darunavir (DRV) may fully prevent infection after oral application and in case of poor adherence (Table 3 and Fig 4). Notably, these compounds have favourable inhibitory quotients (clinically achieved concentrations vastly exceed their  $EC_{50}$ ) and their long elimination half-lives guarantees that inhibitory quotients stay in that favourable range. The drugs maraviroc (MVC) and dolutegravir (DTG) potentially prevent infection but may allow for HIV transmission when individuals poorly adhere to the medication. Notably, the NNRTIs EFV, NVP, RPV and ETR exhibit long elimination half-lives (30–40h) and achieve concentrations required for PrEP to act quickly, and durably. However, there are some safety concerns with liver toxicity, which contraindicate e.g. the use of NVP in uninfected individuals. Liver toxicity to ETR remains to be elucidated in the context of prophylaxis. Skin reactions (ETR and EFV) and neuropsychiatric effects (EFV) have been reported in the context of HIV treatment that need to be evaluated in the context of potential PrEP applications. Likewise, skin reactions and rare liver toxicities with DRV need careful assessment in the context of PrEP repurposing. Moreover, the particular concentration-prophylaxis profile, as depicted in Fig 4, argues for a form of DRV administration that is not dependent on daily dosing for maintaining drug levels (e.g. slow release or nanoparticle formulations). For rilpivirine (RPV), our simulations suggest that near complete protection

can be achieved when concentrations exceed  $EC_{90}$ , Fig 4. RPV is currently investigated as a long-acting formulation in HPTN076 using 1200mg injections every 2 month which yields tough concentrations (median 186 nM) well in excess of this target. However, significant variability is still observed related to gender, and between injections on different occasions [51] which could be incorporated into future model generations. Besides rilpivirine, maraviroc (MVC; 300mg once daily), and raltegravir (RAL) are currently clinically investigated for oral PrEP. Our simulations suggest MVC may incompletely prevent infection even at maximum concentrations and that its efficacy steadily drops with declining levels down to 50% when the drug had not been taken for three days prior to exposure. Results from the NEXT-PrEP (HPTN 069) phase II study observed that MVC may not be potent enough on its own and that among those acquiring HIV infection, MVC concentrations were low, absent or variable [53]. Our model prediction is consistent with the reported lack of efficacy of MVC as PrEP in animals and human explant samples [54] and suggests that the potency of MVC, against infection may be less than its potency in preventing HIV replication ( $EC_{50} > IC_{50}$ ,  $EC_{90} > IC_{90}$ ). However,  $EC_{50}$ ,  $EC_{90}$  estimates for co-receptor antagonists are highly parameter sensitive (S2 Text) warranting further research into elucidating the early infection dynamics. Using the parameters presented in Table 1, we estimate that the  $EC_{90}$  may be around 350nM, which is approximately 70 times larger than its  $IC_{50}$  (conversion formula provided in the results section). Notably, during the dose finding for MVC an  $IC_{90}$  of only 3.9nM (2ng/ml) was considered and this estimate was taken directly to determine target concentrations providing 90% prophylactic efficacy. Other compounds currently under investigation (HPTN-083) [55], but not evaluated in our study are the novel long-acting integrase inhibitor cabotegravir.

Our model has several limitations, but also a number of important advantages. Our simulations do not take into account drug concentrations at the site of mucosal exposure (e.g. cervix, rectum) [51, 56]. These concentrations have, however, not been validated as targets for successful prevention or treatment, whereas data exist (albeit limited) for plasma drug concentrations. Instead, we modelled based on *unbound* concentrations, in line with the broadly accepted ‘free drug hypothesis’. Under the ‘free drug hypothesis’, the unbound concentrations are assumed to be available at the target site to exert pharmacological effects. For drugs highly bound to plasma protein (> 90%), naturally, their *total* concentrations at sites other than the plasma are magnitudes lower [56]. Strikingly, however, the unbound concentrations are identical [57]. Therefore, throughout the work, we assumed, according to the ‘free drug hypothesis’ [58] that the unbound concentrations in plasma and at the target site coincide, where the latter exerts the antiviral effect [59, 60]. All analyzed NNRTIs, InIs and PIs, except for raltegravir (RAL), are highly lipophilic, enabling the *unbound* drug to rapidly cross cellular membranes, generating an equilibrium between the *unbound* drug on either side of the cellular membrane [61]. Even for the weakly lipophilic compound raltegravir, intracellular concentrations are proportional to plasma concentrations by a factor precisely resembling their unbound moiety [62, 63], strongly arguing for the validity of the ‘free drug hypothesis’ for all analyzed drugs. However, ultimate proof in terms of local measurements in humans are lacking currently and may be difficult to obtain experimentally. On the contrary, nucleoside reverse transcriptase inhibitors (NRTIs), which we analysed in a previous work [18] are not expected to obey the ‘free drug hypothesis’ [17, 30, 64]. These compounds need to be actively taken up by cells and converted intracellularly into pharmacologically active triphosphates (NRTI-TP). Since the expression of transporters and intracellular enzymes is likely cell-specific, different cell types may contain vastly different concentrations of pharmacologically active compound. It is therefore entirely unclear what relevance concentration measurements of NRTI-TPs in tissue homogenates [65] (containing HIV target- and non-target cells) from sites of viral exposure (e.g. cervix, rectum) have in terms of prophylaxis.

Utilising the virus exposure model Eqs (23) and (24), we estimated the probability of virus clearance (and the prophylactic efficacy  $\varphi$ ) as a function of the number of viruses ultimately reaching a target cell environment, and not as a function of mucosal exposure. The quantitative role of a number of physiological processes underlying primary infection is currently not fully resolved and impossible to measure in humans (e.g. the cells involved at the local site of exposure, their abundance, locations, their capabilities to transduce virus through physiological barriers and the respective  $R_0$ s). It is known however, that the virus has to overcome a number of physiological bottlenecks/barriers to reach a compartment that permits viral expansion. Despite the mucosal barrier, the sub-mucosal target cell density might initially be low [66], such that only a tiny fraction of viruses find a target cell before being cleared. It has also been reported [66–68], that target cells are subsequently recruited to the site of initial exposure due to inflammation and seminal exposure, mitigating the ‘low target cell bottleneck’ subsequently. If the low target-cell bottleneck is only prevalent during the first replication cycle it can also be modelled by simply considering a smaller virus inoculum that reaches a target-cell environment. In our approach, to obviate model- and parameter uncertainties, we chose a minimal/parsimonious, data-driven approach that treats all physiological barriers as a single bottleneck lumped in terms of the ‘success probability’  $r$  in Eq (24).

The target cell environment herein is a compartment that is decisive for establishing- and shedding infection (this compartment requires  $R_0 > 1$ ). We also assumed that this compartment is well-perfused at the time scale of interest. Under this assumption, viral kinetic parameters measured in plasma coincide with kinetic parameters at the target cell environment, after converting the deterministic reaction parameters to their respective stochastic counterparts (Table 1).

Notably, the model (see Methods section) is calibrated [18] to reflect the per-contact infection risks for typical transmitter virus loads and different modes of sexual exposure (homo- and heterosexual), but can also be adapted to model intravenous exposure by e.g. injection. The calibrated virus exposure model [18] (see Methods section) predicts that either none- or a single infectious virus enter a replication enabling compartment in the majority of hetero-/homosexual contacts. Thus, we suggest that  $EC_{50}(\hat{V})$ ,  $EC_{90}(\hat{V})$  values stated in Table 3 provide a good proxy for the drug-specific prophylactic potency after sexual exposure to HIV (see also S4 Text for a comparison). Importantly, we also observed that increasing the inoculum size decreases the prophylactic efficacy of all drug classes considered (as suggested by increasing  $EC_{50}$  and  $EC_{90}$ ) and increases the steepness of the concentration prophylaxis profile, Fig 3. PIs in particular displayed an almost switch-like prophylactic profile in the case of large inoculum sizes. These observations strikingly indicate that preventive target concentrations can depend on the route of transmission. I.e., intravenous exposure to HIV (larger inoculum sizes compared to sexual exposure) may require higher concentrations for HIV prevention.

When  $R_0(\emptyset)$  is relatively large, we find that our predictions of prophylactic efficacy and -potency for or CRAs, RTIs and InIs are relatively invariant to parameter changes (compare Eqs (25)–(30)). However, we find that when considering an extremely broad range of  $1.7 < R_0(\emptyset) < 112$  values, as in S2 Text, that the parameters used are rather *conservative* in the sense that they disfavour the drugs and may under-predict prophylactic efficacy. With regard to our work’s aim (screen out candidates based on lack-off-, or uncertain potency) such a *conservative* parameter choice should be preferred. For PIs, although highly sensitive to changes  $R_0$  (compare Eqs (31) and (32)) the qualitative statements made (the prophylactic potency is less than suggested by IC50, as well as the steep shape of the concentration-prophylaxis profile) are unaffected for arbitrary, yet realistic parameters, as analysed in S2 Text. However, in the provided software tool ([www.systems-pharmacology.org/prep-predictor](http://www.systems-pharmacology.org/prep-predictor)) it is possible to freely



change all virus dynamics parameters. Notably, Ribero et al. [69] have recently estimated  $R_0 \approx 8$  during *acute* infection ( $\leq 10$  days after exposure, virus is detectable), which is much lower than the value used by us  $R_0 \approx 67$ , which considers viral replication immediately after exposure, in the so-called *eclipse phase* before virus becomes detectable. Our  $R_0$  value is relatively high because we assume a lower CL (clearance of free virus) during this early phase of infection, in line with other modelling approaches [14, 33] and in line with the observation that adaptive immune responses develop only after about 14 days post exposure [70]. However, if we utilise  $CL = 23$  (1/day), as in Ribero et al. [69], we obtain similar values of  $R_0$ .

The knowledge of concentration-prophylaxis relationships between drug classes, and for each component of a particular drug class allows for the intelligent design of PrEP regimens, including how quickly protection can be achieved after a loading dose and how forgiving the regimen is towards missed dosing events. In related article [27] we develop a sophisticated simulation framework that allows to make use of population pharmacokinetic models, to fully explore inter-individual pharmacokinetics and to assess sensitivity towards dosing, individual pharmacokinetic variability and timing of viral challenges.

Our model can be adapted or developed in a number of ways. On a technical side, the analytical solutions provided in the article can be neatly integrated into hybrid stochastic-deterministic algorithms that consider time-varying drug concentrations (pharmacokinetics), as outlined in an accompanying article [27]. In brief, therein we utilize analytic solutions for the extinction probability, Eq (22), to define a set of states where extinction is feasible (*extinction simplex*). Whenever trajectories leave the *extinction simplex*, simulations can be stopped and a hybrid stochastic-deterministic trajectory can be safely classified as an *infection event*. Regarding applications, the separate impact of treatment as prevention [71] (in the case of the donor) versus prophylactic efficacy in the exposed individual can be readily simulated by calibrating the virus load distribution in potential transmitter populations (see ‘exposure model’ in the [Methods](#) section). The effect of PrEP on the transmission of resistance can be estimated by altering  $R_0(\emptyset)$  (the fitness cost of resistance) and by simultaneously increasing  $IC_{50}$  in Eq (10) (extent of resistance). The fitness cost of resistance translates into a decreased transmissibility of resistance in the absence of drugs (Eqs (19)–(21)), while the extent of resistance translates into an increased transmissibility relative to the wildtype at increasing drug concentrations, as e.g. illustrated in [18] (Figure 3 therein). Consequently, provided any transmitted resistance confers some fitness defect, prophylaxis may increase the frequency of transmitted resistance relative to the wildtype, but not its absolute occurrence [18, 72]. Since resistance to HIV drugs generally develops in a stepwise manner, the change in  $EC_{50}$  following acquisition of a resistance mutation can be introduced into this model, to identify a zone of selective pressure for the *de novo* evolution or spread of resistance under PrEP. However, during the early events when the virus infection can still be averted, the population size is too small for resistance to appear *de novo*: A single point mutation appears with probability  $1 - (1 - \mu)^k$  at a particular base, where  $\mu \approx 2.2 \cdot 10^{-5}$  is the per base mutation rate of HIV during reverse transcription [73] and  $k$  is the number of reverse transcription (= cell infection) events. Thus, *de novo* resistance can be assumed to appear, if e.g. PrEP had not been taken at the time of exposure, such that the infection expanded exponentially, and when PrEP is (re-)initiated some time after this early infection has been established. *De novo* resistance development in the context of poor adherence can be modelled in analogy to the work conducted by Rosenbloom et al. [74].

It is well known that the establishment of a latent reservoir is the major barrier to viral extinction during treatment [75] and this reservoir may be established as early as 3 days post infection [76, 77]. In the current framework, we computed viral extinction when  $t \rightarrow \infty$ , assuming drug concentrations stayed constant. Thus, extinction estimates are not affected by the inclusion of a long lived cellular compartment. In an accompanying article [27] we



overcome this assumption, explicitly considering drug pharmacokinetics and e.g. short-course prophylaxis. In the accompanying article infection of long lived cells are considered as an algorithmic stopping criterium: I.e., whenever long lived cells become infected, viral extinction is considered infeasible.

In summary, we have developed a mechanistic modelling tool to *a priori* screen antivirals for their prophylactic utility. Our approach revealed that *in vitro* measured drug potency ( $IC_{50}$ ,  $IC_{90}$ ) should not be used directly to identify lower bound effective concentrations in PrEP trials: With the exception of reverse transcriptase inhibitors, PrEP potency may be less than *in vitro* drug potency, i.e. higher concentrations of drug are required for prophylaxis than suggested by their *in vitro* potency. Consequently, when clinical trial design is guided by *in vitro* drug potency, prophylactic dosing regimen may be selected that attain insufficient concentrations to adequately prevent HIV infection.

Instead, we recommend to use the tool provided ([www.systems-pharmacology.org/prep-predictor](http://www.systems-pharmacology.org/prep-predictor)) to translate *in vitro* drug potency into prophylactic efficacy. We used the developed methods to assess the prophylactic utility of all treatment approved antivirals, allowing to rule out particular candidates by lack-of-, or uncertain prophylactic efficacy. To this end, we presented results using viral dynamics parameters that may under-predict prophylactic efficacy (S2 Text). These preliminary screens indicated that darunavir (DRV), efavirenz (EFV), nevirapine (NVP), etravirine (ETR) and rilpivirine (RPV) may fully prevent infection at concentrations typically achieved during treatment and with an adequate ‘pharmacokinetic margin’. Notably, this prediction is robust across a wide range of (uncertain) parameters (S2 Text). Moreover, we predicted that maraviroc (MVC) and dolutegravir (DTG) can potently prevent infection, but that these drugs do not provide a comparable ‘pharmacokinetic margin’. Furthermore, predictions for MVC are uncertain with respect to viral dynamics parameters (efficacy may both be over- or underpredicted). A next logical step is to further trim this candidate set by ruling out compounds with ominous safety profiles, followed by an assessment of different dosing (roll-out) schemes.

## Supporting information

**S1 Text. The Supplementary Text contains a step-by-step derivation of the equations for the extinction/infection probability presented in the main article.**

(PDF)

**S2 Text. The Supplementary Text contains a sensitivity analysis with respect to viral dynamics parameters.**

(PDF)

**S3 Text. The Supplementary Text contains details of the  $IC_{50}$ -to- $EC_{50}$  conversion.**

(PDF)

**S4 Text. The Supplementary Text compares the  $EC_{50}$  and  $EC_{90}$  (antiviral concentrations that provide 50- and 90% protection) after viral challenge with (i) a single virus  $\hat{V}$ , and after virus challenges (ii) sampled from the distribution for homosexual exposure, Eq (24).**

(PDF)

**S5 Text. The Supplementary Text contains details of the protein-binding adjustment for pharmacodynamic parameters.**

(PDF)

## Author Contributions

**Conceptualization:** Sulav Duwal, Max von Kleist.

**Formal analysis:** Sulav Duwal, Laura Dickinson, Saye Khoo, Max von Kleist.

**Investigation:** Sulav Duwal, Laura Dickinson, Max von Kleist.

**Methodology:** Sulav Duwal, Max von Kleist.

**Project administration:** Saye Khoo, Max von Kleist.

**Software:** Sulav Duwal.

**Supervision:** Saye Khoo, Max von Kleist.

**Writing – original draft:** Sulav Duwal, Max von Kleist.

**Writing – review & editing:** Laura Dickinson, Saye Khoo.

## References

1. Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M, et al. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP uptake, sexual practices, and HIV incidence. *AIDS*. 2014; p. 20–25.
2. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016; 387(10013):53–60. [https://doi.org/10.1016/S0140-6736\(15\)00056-2](https://doi.org/10.1016/S0140-6736(15)00056-2) PMID: 26364263
3. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2015; 372:509–518. <https://doi.org/10.1056/NEJMoa1402269> PMID: 25651245
4. Keller SB, Smith DM. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. *AIDS*. 2011; 25(18):2308–2310. <https://doi.org/10.1097/QAD.0b013e32834d3cab> PMID: 22067201
5. Boffito M, Jackson A, Asboe D. Pharmacology lessons from chemoprophylaxis studies. *Clin Infect Dis*. 2014; 59 Suppl 1:S52–S54. <https://doi.org/10.1093/cid/ciu250> PMID: 24926035
6. AIDS Vaccine Advocacy Coalition. Pre-Exposure Prophylaxis (PrEP) by the Numbers, (available at [http://www.avac.org/sites/default/files/resource-files/prep\\_BTn\\_aug2016.pdf](http://www.avac.org/sites/default/files/resource-files/prep_BTn_aug2016.pdf), accessed 22-Oct-2017.).
7. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. *PLoS Med*. 2013; 10:e1001401. <https://doi.org/10.1371/journal.pmed.1001401> PMID: 23554579
8. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. *J Infect Dis*. 2013; 208:224–234. <https://doi.org/10.1093/infdis/jit150> PMID: 23570850
9. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, Busang L, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. *Sci Rep*. 2011; 1:185. <https://doi.org/10.1038/srep00185> PMID: 22355700
10. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. *PNAS*. 2010; 107:12381–12386. <https://doi.org/10.1073/pnas.1006061107> PMID: 20616092
11. Dimitrov D, Boily MC, Brown ER, Hallett TB. Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. *PloS one*. 2013; 8:e80927. <https://doi.org/10.1371/journal.pone.0080927> PMID: 24282559
12. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. *Cell*. 2013; 155(3):515–518. <https://doi.org/10.1016/j.cell.2013.09.030> PMID: 24243011
13. Conway JM, Konrad BP, Coombs D. Stochastic analysis of pre- and postexposure prophylaxis against HIV infection. *SIAM J Appl Math*. 2013; 73(2):904–28. <https://doi.org/10.1137/120876800>
14. Tuckwell HC, Shipman PD, Perelson AS. The probability of HIV infection in a new host and its reduction with microbicides. *Math Biosci*. 2008; 214(1-2):81–86. <https://doi.org/10.1016/j.mbs.2008.03.005> PMID: 18445499

15. Pearson JE, Krapivsky P, Perelson AS. Stochastic theory of early viral infection: continuous versus burst production of virions. *PLoS Comput Biol*. 2011; 7(2):e1001058. <https://doi.org/10.1371/journal.pcbi.1001058> PMID: 21304934
16. Yan AWC, Cao P, McCaw JM. On the extinction probability in models of within-host infection: the role of latency and immunity. *J Math Biol*. 2016; 73:787–813. <https://doi.org/10.1007/s00285-015-0961-5> PMID: 26748917
17. Duwal S, Schütte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. *PLoS One*. 2012; 7(7):e40382. <https://doi.org/10.1371/journal.pone.0040382> PMID: 22808148
18. Duwal S, Sunkara V, von Kleist M. Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1. *CPT Pharmacometrics Syst Pharmacol*. 2016; 5(7):377–387. <https://doi.org/10.1002/psp4.12095> PMID: 27439573
19. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. *Science*. 2014; 345(6193):1254031. <https://doi.org/10.1126/science.1254031> PMID: 25013080
20. Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. *N Engl J Med*. 1997; 336(15):1072–1078. <https://doi.org/10.1056/NEJM199704103361507> PMID: 9091805
21. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. *Lancet Infect Dis*. 2009; 9(2):118–129. [https://doi.org/10.1016/S1473-3099\(09\)70021-0](https://doi.org/10.1016/S1473-3099(09)70021-0) PMID: 19179227
22. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *PNAS*. 2008; 105(21):7552–7557. <https://doi.org/10.1073/pnas.0802203105> PMID: 18490657
23. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. *J Virol*. 2009; 83(8):3556–3567. <https://doi.org/10.1128/JVI.02132-08> PMID: 19193811
24. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, Leitner T, et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. *PLoS one*. 2010; 5(8):e12303. <https://doi.org/10.1371/journal.pone.0012303> PMID: 20808830
25. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. *PLoS Pathog*. 2010; 6(5):e1000890. <https://doi.org/10.1371/journal.ppat.1000890> PMID: 20485520
26. Allen LJS. *An Introduction to Stochastic Processes with Applications to Biology*. Chapman & Hall/CR; 2011.
27. Duwal S, Dickinson L, Khoo S, von Kleist M. Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. *PLoS Comput Biol*. 2018; 14(6):e1006155. <https://doi.org/10.1371/journal.pcbi.1006155> PMID: 29902179
28. von Kleist M, Menz S, Huisinga W. Drug-class specific impact of antivirals on the reproductive capacity of HIV. *PLoS Comput Biol*. 2010; 6(3):e1000720. <https://doi.org/10.1371/journal.pcbi.1000720> PMID: 20361047
29. von Kleist M, Menz S, Stocker H, Arasteh K, Schütte C, Huisinga W. HIV Quasispecies Dynamics during Pro-active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs. *PLoS One*. 2011; 6(3):e18204. <https://doi.org/10.1371/journal.pone.0018204> PMID: 21455303
30. Duwal S, von Kleist M. Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1. *Eur J Pharm Sci*. 2016; 94:72–83. <https://doi.org/10.1016/j.ejps.2016.01.016> PMID: 26796142
31. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. *J Virol*. 2009; 83(16):8208–8220. <https://doi.org/10.1128/JVI.00296-09> PMID: 19515785
32. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. *J Virol*. 2013; 87(13):7218–7233. <https://doi.org/10.1128/JVI.03577-12> PMID: 23616655
33. Tan WY, Wu H. Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. *Math Biosci*. 1998; 147(2):173–205. [https://doi.org/10.1016/S0025-5564\(97\)00094-1](https://doi.org/10.1016/S0025-5564(97)00094-1) PMID: 9433062

34. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling plasma virus concentration during primary HIV infection. *J Theor Biol.* 2000; 203(3):285–301. <https://doi.org/10.1006/jtbi.2000.1076> PMID: 10716909
35. Perelson AS. Modelling viral and immune system dynamics. *Nat Rev Immunol.* 2002; 2(1):28–36. <https://doi.org/10.1038/nri700> PMID: 11905835
36. Perelson AS, Kirschner DE, De Boer R. Dynamics of HIV infection of CD4+ T cells. *Math Biosci.* 1993; 114(1):81–125. [https://doi.org/10.1016/0025-5564\(93\)90043-A](https://doi.org/10.1016/0025-5564(93)90043-A) PMID: 8096155
37. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. *J Virol.* 2002; 76(17):8518–8531. PMID: 12163571
38. Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. *J Virol.* 2005; 79(4):2199–2210. <https://doi.org/10.1128/JVI.79.4.2199-2210.2005> PMID: 15681422
39. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol Rev.* 2006; 58(3):621–681. <https://doi.org/10.1124/pr.58.3.10>
40. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nat Med.* 2008; 14(7):762–766. <https://doi.org/10.1038/nm1777> PMID: 18552857
41. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. *J R Soc Interface.* 2005; 2:281–293. <https://doi.org/10.1098/rsif.2005.0042> PMID: 16849186
42. Joseph SB, Swanstrom R, Kashuba ADM, Cohen MS. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. *Nat Rev Microbiol.* 2015; 13(7):414–25. <https://doi.org/10.1038/nrmicro3471> PMID: 26052661
43. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. *Lancet Infect Dis.* 2008; 8(9):553–563. [https://doi.org/10.1016/S1473-3099\(08\)70156-7](https://doi.org/10.1016/S1473-3099(08)70156-7) PMID: 18684670
44. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med.* 2000; 342(13):921–929. <https://doi.org/10.1056/NEJM200003303421303> PMID: 10738050
45. Mellors JW, Rinaldo C Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science.* 1996; 272(5265):1167–1170. <https://doi.org/10.1126/science.272.5265.1167> PMID: 8638160
46. Yousef KP, Meixenberger K, Smith MR, Somogyi S, Gromöller S, Schmidt D, et al. Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses. *JAIDS Journal of Acquired Immune Deficiency Syndromes.* 2016; 73(3):356–363. <https://doi.org/10.1097/QAI.0000000000001122>
47. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. *Lancet.* 2008; 372(9635):314–320. [https://doi.org/10.1016/S0140-6736\(08\)61115-0](https://doi.org/10.1016/S0140-6736(08)61115-0) PMID: 18657710
48. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS.* 2009; 23(11):1397–1404. <https://doi.org/10.1097/QAD.0b013e32832b7dca> PMID: 19381076
49. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. *J Infect Dis.* 2012; 205(3):358–365. <https://doi.org/10.1093/infdis/jir747> PMID: 22241800
50. von Kleist M, Metzner P, Marquet R, Schütte C. HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. *PLoS Comput Biol.* 2012; 8(1):e1002359. <https://doi.org/10.1371/journal.pcbi.1002359> PMID: 22275860
51. McGowan I, Dezzutti CS, Siegel A, Engstrom J, Nikiforov A, Duffill K, et al. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. *Lancet HIV.* 2016; 3:e569–e578. [https://doi.org/10.1016/S2352-3018\(16\)30113-8](https://doi.org/10.1016/S2352-3018(16)30113-8) PMID: 27658864
52. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. *The New England journal of medicine.* 2012; 367:411–422. <https://doi.org/10.1056/NEJMoa1202614> PMID: 22784040
53. Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, et al. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With

- Men (HPTN 069/ACTG A5305). *Journal Infect Dis.* 2017; 215:238–246. <https://doi.org/10.1093/infdis/jiw525> PMID: 27811319
54. McGowan I, Nikiforov A, Young A, Cranston R, Landovitz RJ, Bakshi R, et al. PrEP Impact on T-Cell Activation and Explant Infection: HPTN 069/ACTG 5305 Substudy. In: CROI2016, Boston. Oral presentation 104; 2016.
  55. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. *Lancet HIV.* 2017; 4:e331–e340. [https://doi.org/10.1016/S2352-3018\(17\)30068-1](https://doi.org/10.1016/S2352-3018(17)30068-1) PMID: 28546090
  56. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. *Antivir Ther.* 2011; 16:1149–1167. <https://doi.org/10.3851/IMP1919> PMID: 22155899
  57. Avery LB, Bakshi RP, Cao YJ, Hendrix CW. The male genital tract is not a pharmacological sanctuary from efavirenz. *Clin Pharmacol Ther.* 2011; 90:151–156. <https://doi.org/10.1038/clpt.2011.99> PMID: 21633344
  58. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov.* 2010; 9(12):929–939. <https://doi.org/10.1038/nrd3287> PMID: 21119731
  59. Watkins WJ, Desai MC. HCV versus HIV drug discovery: Déjà vu all over again? *Bioorg Med Chem Lett.* 2013; 23(8):2281–2287. <https://doi.org/10.1016/j.bmcl.2013.02.070> PMID: 23489621
  60. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. *AIDS Res Hum Retroviruses.* 2003; 19(9):825–835. <https://doi.org/10.1089/088922203769232629> PMID: 14585213
  61. von Kleist M, Huisinga W. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution. *J Pharmacokinet Pharmacodyn.* 2007; 34:789–806. <https://doi.org/10.1007/s10928-007-9071-3> PMID: 17899329
  62. Sandkovsky U, Swindells S, Robbins BL, Nelson SR, Acosta EP, Fletcher CV. Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. *AIDS.* 2012; 26:2257–2259. <https://doi.org/10.1097/QAD.0b013e328359a978> PMID: 22948265
  63. Wang L, Soon GH, Seng KY, Li J, Lee E, Yong EL, et al. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. *Antimicrob Agents Chemother.* 2011; 55:4090–4095. <https://doi.org/10.1128/AAC.00593-11> PMID: 21746959
  64. von Kleist M, Huisinga W. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. *Eur J Pharm Sci.* 2009; 36(4-5):532–543. <https://doi.org/10.1016/j.ejps.2008.12.010> PMID: 19150497
  65. Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A Translational Pharmacology Approach to Predicting HIV Pre-Exposure Prophylaxis Outcomes in Men and Women Using Tenofovir Disoproxil Fumarate +/- Emtricitabine. *J Infect Dis.* 2016.
  66. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. *Nature.* 2010; 464(7286):217–23. <https://doi.org/10.1038/nature08757> PMID: 20220840
  67. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. *Nature.* 2009; 458(7241):1034–8. <https://doi.org/10.1038/nature07831> PMID: 19262509
  68. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. *PLoS Pathog.* 2009; 5(1):e1000274. <https://doi.org/10.1371/journal.ppat.1000274> PMID: 19165325
  69. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. *J Virol.* 2010; 84(12):6096–102. <https://doi.org/10.1128/JVI.00127-10> PMID: 20357090
  70. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. *Nat Rev Immunol.* 2010; 10(1):11–23. <https://doi.org/10.1038/nri2674> PMID: 20010788
  71. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.* 2011; 365(6):493–505. <https://doi.org/10.1056/NEJMoa1105243> PMID: 21767103
  72. Frank M, von Kleist M, Kunz A, Harms G, Schütte C, Kloft C. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. *Antimicrob*



- Agents Chemother. 2011; 55(12):5529–5540. <https://doi.org/10.1128/AAC.00741-11> PMID: 21947390
73. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. *J Virol.* 1995; 69:5087–5094. PMID: 7541846
  74. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. *Nat Med.* 2012; 18:1378–1385. <https://doi.org/10.1038/nm.2892> PMID: 22941277
  75. Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. *Nat Immunol.* 2015; 16(6):584–589. <https://doi.org/10.1038/ni.3152> PMID: 25990814
  76. Whitney JB, Hill AL, Sanisetty S, Penalosa-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. *Nature.* 2014; 512:74–77. <https://doi.org/10.1038/nature13594> PMID: 25042999
  77. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *PNAS.* 1998; 95:8869–8873. <https://doi.org/10.1073/pnas.95.15.8869> PMID: 9671771
  78. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature.* 1995; 373(6510):117–122. <https://doi.org/10.1038/373117a0> PMID: 7529365
  79. Sedaghat AR, Siliciano RF, Wilke CO. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. *Antivir Ther.* 2009; 14(2):263–271. PMID: 19430101
  80. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. *PNAS.* 2008; 105(12):4832–4837. <https://doi.org/10.1073/pnas.0711372105> PMID: 18362342
  81. Markowitz M, Louie M, Hurley A, Sun E, Mascio MD, Perelson AS, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. *J Virol.* 2003; 77:5037–5038. <https://doi.org/10.1128/JVI.77.8.5037-5038.2003> PMID: 12663814
  82. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. *J Infect Dis.* 2008; 197(3):411–419. <https://doi.org/10.1086/525283> PMID: 18248304
  83. Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. *J Antimicrob Chemother.* 2005; 56(4):738–744. <https://doi.org/10.1093/jac/dki308> PMID: 16141277
  84. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. *Clin Pharmacol Ther.* 1997; 61(5):531–543. [https://doi.org/10.1016/S0009-9236\(97\)90133-8](https://doi.org/10.1016/S0009-9236(97)90133-8) PMID: 9164415
  85. Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Prince HMA, et al. Single and multiple dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. *J Acquir Immune Defic Syndr.* 2012; 61(2):138. <https://doi.org/10.1097/QAI.0b013e31825cb645> PMID: 22614898
  86. Schöller-Gyüre M, Kakuda TN, Raouf A, De Smedt G, Hoetelmans RM. Clinical pharmacokinetics and pharmacodynamics of etravirine. *Clinical pharmacokinetics.* 2009; 48(9):561–574. <https://doi.org/10.2165/10895940-000000000-00000> PMID: 19725591
  87. Dickinson L, Bracchi M, Elliot E, Else L, Khoo S, Back D, et al. Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In: *Journal of the International AIDS Society.* vol. 19. INT AIDS SOCIETY AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND; 2016.
  88. Delille CA, Pruet ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, et al. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. *J Clin Pharmacol.* 2014; 54(9):1063–1071. <https://doi.org/10.1002/jcph.298> PMID: 24691856
  89. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA, Group HNRC, et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. *Antimicrobial agents and chemotherapy.* 2000; 44(8):2173–2175. <https://doi.org/10.1128/AAC.44.8.2173-2175.2000> PMID: 10898694
  90. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, et al. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. *Drug Metab Dispos.* 2001; 29(3):299–303. PMID: 11181499
  91. Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. *JAIDS.* 2001; 27(4):344–349. PMID: 11468422



92. Laskey SB, Siliciano RF. Quantitative evaluation of the antiretroviral efficacy of dolutegravir. *JCI Insight*. 2016; 1(19):e90033. <https://doi.org/10.1172/jci.insight.90033> PMID: 27882352
93. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. *Nat Med*. 2012; 18(3):446–451. <https://doi.org/10.1038/nm.2649> PMID: 22344296
94. Dickinson L, Bracchi M, Elliot E, Else L, Khoo S, Back D, et al. Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In: International Congress of Drug Therapy in HIV Infection, Glasgow, UK. Abstract P094; 2016.
95. Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. *J Clin Pharmacol*. 2014; 54(2):133–140. <https://doi.org/10.1002/jcph.222> PMID: 24203510
96. Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, et al. Pharmacokinetic interactions of maraviroc with darunavir/ritonavir, maraviroc with etravirine, and maraviroc with etravirine/darunavir/ritonavir in healthy volunteers: results of two drug interaction trials. *Antimicrob Agents Chemother*. 2011; 55:2290–6. <https://doi.org/10.1128/AAC.01046-10> PMID: 21383098